1-855-378-42281-855-378-4228
One of the outpatient treatment alternatives for clients in Vernon Center who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Some facilities and doctors are certified to give specific medications to opioid addicted people, many that are opioids themselves and are addiction. With low amounts however, the user doesn't feel high and also doesn't have intense cravings and isn't experiencing opioid withdrawal. Methadone is the first med administered for this reason, but there are alternative choices to select from.
Methadone is an opiate and is meant to be taken at an outpatient medical center certified to dispense the drug, which is taken on a daily basis as a pill or liquid. The cost of the med is about $150 per month. Buprenorphine is also an opiate based med, and is in pill form often taken one day on, one day off. But different from Methadone that is only be given in well-regulated medical centers, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is about three hundred dollars monthly for the generic version of the drug. There is also a version of buprenorphine containing the drug naloxone, which is a drug that blocks the effects of opiates. An individual taking this formulation, AKA Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and is priced around $450 per month. Naltrexone is an additional med used in opioid maintenance therapy, but unlike the other medications mentioned here it's an opiate blocker and isn't an opiate. A person has the choice to take this medication as a monthly injection, and that is called Vivitrol. As an opioid blocker, it prevents a person from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 a month.
For All Alcohol and Drug Rehabilitation Programs In Vernon Center, Click Here.
